Pertuzumab is a dual HER2/HER3 monoclonal antibody approved in combination with trastuzumab and taxane-based chemotherapy for first-line therapy in HER2-positive metastatic BC and in adjuvant and neoadjuvant settings. Here, ERBB2 is linked to breast cancer.